← Search another drug
PatientPulse · by PatientPartner
Entresto sacubitril/valsartan
High confidence
~59 public patient conversations and reviews referenced across forums, review sites, and patient blogs
Executive intelligence
The signal that moves starts & adherence
42%Positive sentiment in discussion
114,605FDA adverse-event reports
51%Flagged serious
36%Reports name female patients
The single biggest commercial risk is not efficacy doubt but early-weeks side-effect overwhelm: patients who survive the "first-week wobble" on blood pressure and fatigue become long-term brand advocates, while those who quit in weeks 1-4 do so silently and never return.
- EF recovery stories (20% to 50-60%) are the brand's most powerful word-of-mouth asset, but they only surface after 6-12 months, leaving a dangerous sentiment gap in the first 4-8 weeks.
- Hypotension is the dominant adherence-killer: patients on complex multi-drug regimens (furosemide, bisoprolol, dapagliflozin) frequently cannot tolerate even the starting 24/26 mg dose without syncope, demanding proactive BP-management messaging.
- Cost and insurance friction is a rising, distinct conversation layer separate from tolerability: Medicare Part D formulary confusion, generic-vs-brand anxiety, and out-of-pocket sticker shock each represent a discrete drop-off point.
- A vocal minority of long-term users (6 plus years) who stabilized or improved EF function as informal peer ambassadors across BHF HealthUnlocked and Mayo Clinic Connect, representing an under-leveraged patient-services asset.